Table 2 Clinicopathologic associations with PGR variants

From: Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer

Factor Wild-type Variant p value
Bone metastasis
  No 8 (35%) 15 (65%) 0.99
  Yes 4 (31%) 9 (69%)  
Brain metastasis
  No 11 (37%) 19 (63%) 0.64
  Yes 1 (17%) 5 (83%)  
Chest wall metastasis
  No 10 (30%) 23 (70%) 0.25
  Yes 2 (67%) 1 (33%)  
Liver metastasis
  No 11 (34%) 21 (66%) 0.99
  Yes 1 (25%) 3 (75%)  
Lung/pleura metastasis
  No 10 (31%) 22 (69%) 0.59
  Yes 2 (50%) 2 (50%)  
Lymph node metastasis    
  No 10 (33%) 20 (67%) 0.99
  Yes 2 (33%) 4 (67%)  
Treatment
  Aromatase inhibitor only 4 (44%) 5 (56%) 0.61
  Tamoxifen only 4 (27%) 11 (73%)  
  Both 4 (33%) 8 (67%)  
PR immunohistochemistry
  Negative 3 (23%) 10 (77%) 0.47
  Positive 9 (39%) 14 (61%)  
HER2 status
  Negative 5 (25%) 15 (75%) 0.81
  Positive 2 (25%) 6 (75%)  
  Equivocal 1 (100%) 0 (0%)